Creative Biolabs, a world-leading service provider of antibody development, has launched a series of in vitro diagnostic (IVD) antibody development services targeting the M2-PK biomarker, which are available for our clients worldwide. A group of experienced scientists and experts that are focused on IVD antibody development are pleased to help you develop high-quality IVD antibodies for the M2-PK marker.
M2-pyruvate kinase (M2-PK), also known as tumor M2-PK, is an isoenzyme of pyruvate kinase. It is identified as an essential enzyme in glycolysis in which it catalyzes the conversion of phosphoenolpyruvate to pyruvate. M2-PK is also known as an oncoprotein which plays a key role in tumor metabolism. Generally, it is a highly active, tetrameric form. However, when exposed to oncoproteins in tumor tissues, M2-PK will be altered to a less active dimeric form. This change is essential for tumor metabolism. M2-PK has been found in blood and stool in a wide range of cancers, including gastric, esophageal, kidney, lung, colorectal, pancreatic, breast, and ovarian cancer. Thus, it has been considered to be a useful marker for cancer screening, diagnosis or detection, as well as disease follow-up to detect recurrence.
Fig.1 Metabolic consequences of the dimerization of M2-PK.1
Cholangiocarcinoma (CCA), also known as bile duct cancer or biliary tract cancer, is regarded as a fatal disease which is always diagnosed late and treated inefficiently. As the morbidity and mortality rates for CCA increase significantly, patients suffered from CCA currently have a poor prognosis. However, if it would be possible to diagnose CCA in the early stage while effective therapeutic methods would be available, the CCA patients would achieve a better quality of life. Therefore, the diagnosis and treatment of CCA in the early stage is in need of urgent investigative attention. Previous studies showed that the level of serum M2-PK in CCA patients was notably higher than that of controls and exhibited high sensitivity and specificity. Consequently, M2-PK can be considered as a promising marker for diagnosing CCA.
IVD antibodies can be used in disease screening, therapy monitoring, and prognosis of different diseases. As a novel tumor metabolic marker, M2-PK plays an essential role in tumor metabolism and energy production by channeling glucose carbons, either into synthetic processes or toward glycolytic energy production. The amount of M2-PK in the stool and EDTA-plasma can reflect the specific metabolic status of the tumors. Now, Creative Biolabs can provide the most comprehensive IVD antibody development services for M2-PK, using our advanced technology platforms. We are specialized in antibody conjugation to different labels. Moreover, we help develop high-quality IVD immunoassays of different formats, giving expert support in feasibility analysis, protocol establishment, assay design, validation, and kit production.
We have achieved a lot of projects for our clients based on years of experience. Contact us to get more information and discuss your project goals.
Reference
For Research Use Only.
